Full Press Release Details
Zynex Announces 2019 Second Quarter Earnings
Revenue increased 36% year over year to $10.3 million
Orders increased 65% year over year
Net income $2.2 million; Diluted EPS $0.06
Adjusted EBITDA $2.8M
consecutive quarter of positive net income
CO - July 31, 2019 - Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture
and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics,
today reported financial results for its second quarter ended June 30, 2019.
Second Quarter Financial Results Summary:
For the second quarter, the Company reported net revenue of
$10.3 million, a 36% increase over Q2-2018. Gross margins were 81% in the second quarter of 2019 and net income was $2.2 million.
Adjusted EBITDA was $2.8 million in the second quarter of 2019
The Company generated $2.4 million of cash from operations during
the second quarter of 2019. As of June 30, 2019, the Company had working capital of $11.9 million compared to $7.3 million at December
31, 2018. Cash on hand was $10.1 million at the end of the second quarter.
President and CEO Commentary:
Thomas Sandgaard, CEO said: "We followed our strong first
quarter with continued growth in the second quarter with revenue of $10.3 million and net income of $2.2 million. Orders grew 65%
compared to the second quarter of 2018 and were 48% higher year to date compared to the first half of 2018.
In the second quarter, we continued to expand our sales force.
We expect the addition of new sales reps to have an impact on order and revenue growth this year and going forward.
We continue to advocate for pain patients, and for physicians
to prescribe our NexWave technology as the first line of defense in treating chronic and acute pain without side effects. We are
dedicated to promoting our technology in an effort to remove patient addiction and other side effects from prescription opioids."
Third Quarter 2019 Guidance:
The estimate range for the third quarter revenue is between
$10.7 and $11.2 million with Adjusted EBITDA between $2.4 and $2.9 million as we continue to invest in growing our sales force.
The revenue estimate is approximately 32% to 38% above last year's third quarter revenue of $8.1 million.
Conference Call and Webcast Details:
Wednesday, July 31, 2019 at 2:15 p.m. MT - 4:15
To register and participate in the webcast, interested parties
should click on the following link or dial in approximately 10-15 minutes prior to the webcast:
| US PARTICIPANT DIAL IN (TOLL FREE): | 1-844-825-9790 |
| INTERNATIONAL DIAL IN: | 1-412-317-5170 |
| Canada Toll Free: | 1-855-669-9657 |
Zynex reports its financial results in accordance with accounting
principles generally accepted in the U.S. (GAAP). In addition, the Company is providing in this news release financial information
in the form of Adjusted EBITDA (earnings before interest, taxes, depreciation, amortization, other income/expense and stock compensation).
Management believes these non-GAAP financial measures are useful to investors and lenders in evaluating the overall financial health
of the Company in that they allow for greater transparency of additional financial data routinely used by management to evaluate
performance. Adjusted EBITDA can be useful for investors or lenders as an indicator of earnings available to service debt. Non-GAAP
financial measures should not be considered in isolation from or as an alternative to the financial information prepared in accordance
Zynex, founded in 1996,
markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company's
proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex is also developing a new
blood volume monitor for use in hospitals and surgery centers. For additional information, please visit: Zynex.com.
Safe Harbor Statement
Certain statements in
this release are "forward-looking" or projections and as such are subject to numerous risks and uncertainties. The company
makes no express or implied representation or warranty as to the completeness of this information or, in the case of projections,
as to their attainability or the accuracy and completeness of the assumptions from which they are derived. Actual results may vary
significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ
from forward-looking statements include, but are not limited to, the need to obtain FDA clearance and CE marking of new products,
the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial
resources, the need to keep pace with technological changes, our dependence on the reimbursement for our products from health insurance
companies, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of
our sales strategy including a strong direct sales force and other risks described in our filings with the Securities and Exchange
Commission including the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31,
2018 as well as Forms 10-Q, 8-K and 8-K/A, press releases and the Company's website.
Investor Relations Contact:
Amato and Partners, LLC
Investor Relations Counsel
CONSOLIDATED BALANCE SHEETS
(AMOUNTS IN THOUSANDS)
| June 30, | December 31, | |||||||
| 2019 | 2018 | |||||||
| (as adjusted) | ||||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash | $ | 10,054 | $ | 10,128 | ||||
| Accounts receivable, net | 3,540 | 2,791 | ||||||
| Inventory, net | 1,325 | 837 | ||||||
| Prepaid expenses and other | 833 | 568 | ||||||
| Total current assets | 15,752 | 14,324 | ||||||
| Property and equipment, net | 822 | 819 | ||||||
| Operating lease asset | 4,323 | 3,050 | ||||||
| Financing lease asset | 9 | 19 | ||||||
| Deposits | 342 | 314 | ||||||
| Long term deferred income taxes | 591 | 725 | ||||||
| Total assets | $ | 21,839 | $ | 19,251 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable and accrued expenses | 1,829 | 1,552 | ||||||
| Lease liability - operating leases | 965 | 671 | ||||||
| Lease liability - financing leases | 14 | 14 | ||||||
| Income taxes payable | - | 688 | ||||||
| Dividends payable | 11 | 2,270 | ||||||
| Accrued payroll and related taxes | 1,009 | 908 | ||||||
| Deferred insurance reimbursement | - | 880 | ||||||
| Total current liabilities | 3,828 | 6,983 | ||||||
| Long-term liabilities: | ||||||||
| Lease liability - operating leases | 3,940 | 2,967 | ||||||
| Lease liability - financing leases | 4 | 10 | ||||||
| Total liabilities | 7,772 | 9,960 | ||||||
| Stockholders' equity: | ||||||||
| Preferred stock | - | - | ||||||
| Common stock | 34 | 34 | ||||||
| Additional paid-in capital | 8,592 | 8,157 | ||||||
| Treasury stock | (3,846 | ) | (3,675 | ) | ||||
| Accumulated earnings | 9,376 | 4,864 | ||||||
| Total Zynex, Inc. stockholders' equity | 14,156 | 9,380 | ||||||
| Non-controlling interest | (89 | ) | (89 | ) | ||||
| Total stockholders' equity | 14,067 | 9,291 | ||||||
| Total liabilities and stockholders' equity | $ | 21,839 | $ | 19,251 |
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | |||||||||||||||
| 2019 | 2018 | 2019 | 2018 | |||||||||||||
| NET REVENUE | ||||||||||||||||
| Devices | $ | 2,288 | $ | 1,673 | $ | 4,263 | $ | 3,261 | ||||||||
| Supplies | 8,009 | 5,900 | 15,230 | 11,189 | ||||||||||||
| Total net revenue | 10,297 | 7,573 | 19,493 | 14,450 | ||||||||||||
| COSTS OF REVENUE AND OPERATING EXPENSES | ||||||||||||||||
| Costs of revenue - rental, product & supply | 1,948 | 1,330 | 3,732 | 2,566 | ||||||||||||
| Sales and marketing | 3,081 | 1,457 | 5,554 | 2,763 | ||||||||||||
| General and administrative | 2,684 | 2,071 | 5,367 | 4,450 | ||||||||||||
| Total costs of revenue and operating expenses | 7,713 | 4,858 | 14,653 | 9,779 | ||||||||||||
| Income from operations | 2,584 | 2,715 | 4,840 | 4,671 | ||||||||||||
| Other income (expense) | ||||||||||||||||
| Deferred insurance reimbursement | - | - | 880 | - | ||||||||||||
| Interest expense | - | (37 | ) | - | (153 | ) | ||||||||||
| Other income (expense), net | - | (37 | ) | 880 | (153 | ) | ||||||||||
| Income from operations before income taxes | 2,584 | 2,678 | 5,720 | 4,518 | ||||||||||||
| Income tax expense | 422 | 260 | 1,208 | 179 | ||||||||||||
| Net Income | $ | 2,162 | $ | 2,418 | $ | 4,512 | $ | 4,339 | ||||||||
| Net income per share: | ||||||||||||||||
| Basic | $ | 0.07 | $ | 0.07 | $ | 0.14 | $ | 0.13 | ||||||||
| Diluted | $ | 0.06 | $ | 0.07 | $ | 0.13 | $ | 0.13 | ||||||||
| Weighted average basic shares outstanding | 32,326 | 32,620 | 32,279 | 32,610 | ||||||||||||
| Weighted average diluted shares outstanding | 33,953 | 34,169 | 33,837 | 34,291 |
Reconciliation of GAAP to Non-GAAP Measures
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | |||||||||||||||
| 2019 | 2018 | 2019 | 2018 | |||||||||||||
| Net income | $ | 2,162 | $ | 2,418 | $ | 4,512 | $ | 4,339 | ||||||||
| Depreciation and Amortization | 76 | 42 | 142 | 68 | ||||||||||||
| Stock-based compensation expense | 158 | 53 | 297 | 116 | ||||||||||||
| Other (income)/expense, net | - | 37 | (879 | ) | 153 | |||||||||||
| Income tax expense (benefit) | 422 | 260 | 1,208 | 179 | ||||||||||||
| Adjusted EBITDA | $ | 2,818 | $ | 2,810 | $ | 5,280 | $ | 4,855 | ||||||||
| % of Net Revenue | 27 | % | 37 | % | 27 | % | 34 | % |